Life Edit Therapeutics
Tyler Smith is a Scientist I specializing in RNA technology development at Life Edit Therapeutics since October 2023. Previously, at Enumera Molecular from August 2022 to August 2023, Tyler focused on developing assays and diagnostic tools for women's health using a biochemistry, microbiology, and organic chemistry approach. As a PhD candidate at the University of Michigan from August 2017 to August 2022, Tyler designed an in vitro assay to investigate protein synthesis mechanisms, studying tRNA modifications and their effects on translation efficiency and accuracy. Tyler holds a Doctor of Philosophy in Biochemistry from the University of Michigan and a Bachelor of Science in Chemistry from Truman State University.
Life Edit Therapeutics
Life Edit, an ElevateBio company, is a next-generation genome editing company that has built a highly innovative platform with one of the world’s largest and most diverse collections of novel RNA-guided nucleases (RGNs) and base editors. The platform allows Life Edit to target any genomic sequence and develop novel human therapeutics for the most challenging genetic diseases by enabling ex vivo engineering for cell therapies and regenerative medicines and in vivo delivery of gene therapies. In addition to developing its own pipeline of cell and gene therapies, Life Edit Therapeutics will continue to strengthen its platform of genome-editing enzymes, provide gene-editing expertise to strategic partners, and form other third-party partnerships to discover and develop new therapies.